Home
ACE Reports
All Specialties All Specialties All Specialties Arthroplasty Arthroplasty Arthroplasty Evidence Based Medicine Evidence Based Medicine Evidence Based Medicine Foot & Ankle Foot & Ankle Foot & Ankle General Orthopaedics General Orthopaedics General Orthopaedics Hand & Wrist Hand & Wrist Hand & Wrist Metabolic Disorders Metabolic Disorders Metabolic Disorders Osteoarthritis Osteoarthritis Osteoarthritis Pediatric Orthopaedics Pediatric Orthopaedics Pediatric Orthopaedics Peri-Operative Peri-Operative Peri-Operative Physical Therapy & Rehab Physical Therapy & Rehab Physio & Rehab Shoulder & Elbow Shoulder & Elbow Shoulder & Elbow Spine Spine Spine Sports Medicine Sports Medicine Sports Medicine Trauma Trauma Trauma Tumour Tumour Tumour Author Interviews Author Interviews Author Interview Conference Report Conference Report Conference Reports
Original Content
News
Multimedia
About
Search
Home
ACE Reports
Arthroplasty Evidence Based Medicine Foot & Ankle General Orthopaedics Hand & Wrist Metabolic Disorders Osteoarthritis Pediatric Orthopaedics Peri-Operative Physical Therapy & Rehab Shoulder & Elbow Spine Sports Medicine Trauma Tumour Author Interviews Conference Report
Original Content
News
Multimedia
About
Search
Previous Ace Report Leucocyte- and platelet-rich fibrin have no effect on outcomes of rotator cuff repair Next Ace Report Leucocyte- and platelet-rich fibrin have no effect on outcomes of rotator cuff repair
Ace Report Cover
Spine
CT-P13 comparable to infliximab at 54 weeks for ankylosing spondylitis
Reprints
Cite This
Reprints
Cite This
AceReport Image
Spine
CT-P13 comparable to infliximab at 54 weeks for ankylosing spondylitis
Verified
This report has been verified by one or more authors of the original publication.
Arthritis Res Ther. 2016 Jan 20;18(1):25
Contributing Authors

W Park DH Yoo J Jaworski J Brzezicki A Gnylorybov V Kadinov IG Sariego C Abud-Mendoza WJ Escalante SW Kang D Andersone F Blanco SS Hong SH Lee J Braun

250 ankylosing spondylitis patients were randomized to receive 5mg/kg of either CT-P13 or Infliximab through intravenous infusion for 54 weeks. The purpose of this study was to compare CT-P13, a biosimilar drug, to a known efficacious treatment of this pathology to determine its efficacy, immunogenicity, pharmacokinetics, and safety. The findings displayed similar results between groups for all patient reported efficacy outcomes, adverse events, and pharmacokinetic parameters, as well as in the proportion of patients testing positive for anti-drug antibodies at 54 weeks.

Unlock the full article

Get unlimited access to OrthoEvidence with a free trial
Start Trial

Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics

Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics

Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions

Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics

Or continue reading this full article
Register Now
AskOE
Search
Close Search Window
Welcome Back!
Forgot Password?
Create an Account

Account will be affiliated with

OR
Forgot Password?
OR
Check your email

If an account exists with the provided email address, a password reset email will be sent to you. If you don't see the email, please check your spam or junk folder.

For further assistance, contact our support team.

Cite this Ace Report

OrthoEvidence. CT-P13 comparable to infliximab at 54 weeks for ankylosing spondylitis. ACE Report. 2016;6(6):24. Available from: https://myorthoevidence.com/AceReport/Report/ct-p13-comparable-to-infliximab-at-54-weeks-for-ankylosing-spondylitis

Copy Citation
Share this Ace Report